RxDoctor Payments Data

Allison Miller

Family · Hawley, PANPI 1912578527

Payments from drug & device makers

$4,427in general payments, 2019–2025

Across 39 payments — averaging $113.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sobi, Inc$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$140
  • Indivior Inc.$105
  • Braeburn Inc.$64
  • Alkermes, Inc.$61
  • Novo Nordisk$52
  • plus $114 from 4 others

What the payments were for

  • Speaking & faculty fees$2,34053%
  • Travel & lodging$1,24328%
  • Food & beverage$84419%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,427 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,057
Medicare patients
31
Services billed
56

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$30,751
OzempicSemaglutide29$29,782
EliquisApixaban26$15,695
TrulicityDulaglutide12$11,017
InvokanaCanagliflozin13$8,359
Breo ElliptaFluticasone/Vilanterol21$8,327
Repatha SureclickEvolocumab14$7,553
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$5,691
Albuterol Sulfate HfaAlbuterol Sulfate63$1,188
Atorvastatin Calcium107$1,141
Pantoprazole Sodium59$1,031
Duloxetine Hcl31$954
FenofibrateFenofibrate Nanocrystallized13$924
Losartan Potassium81$882
Levothyroxine Sodium73$859

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$15$41,76831 claims
Novo NordiskOzempic$52$29,78229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in Hawley

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →